Breast cancer is a hormone-dependent cancer and usually treated with endocrine therapy using aromatase inhibitors or anti-estrogens such as tamoxifen. A majority of breast cancer, however, will often fail to respond to endocrine therapy. In the present study, we explored miRNAs associated with endocrine therapy resistance in breast cancer. High-throughput miRNA sequencing was performed using RNAs prepared from breast cancer MCF-7 cells and their derivative clones as endocrine therapy resistant cell models, including tamoxifen-resistant (TamR) and long-term estrogen-deprived (LTED) MCF-7 cells. Notably, miR-21 was the most abundantly expressed miRNA in MCF-7 cells and overexpressed in TamR and LTED cells. We found that miR-378a-3p expression...
Resistance to tamoxifen (Tam), a widely used antagonist of the estrogen receptor (ER), is a common o...
Background Endocrine resistance is a major hurdle in breast cancer management, and determining the u...
<div><p>Introduction</p><p>The role of miRNAs in acquired endocrine-resistant breast cancer is not f...
Breast cancer is a hormone-dependent cancer and usually treated with endocrine therapy using aromata...
Abstract Background Tumor resistance to the selective estrogen receptor modulator tamoxifen remains ...
Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast can...
Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast canc...
Abstract no. 151Tamoxifen is a selective estrogen receptor modifier competing for binding with estro...
Poster Session 3 - PO.CB.13.01: MicroRNA-Mediated Regulation of Cancer Biology 2: abstract no. 2040T...
We explored the role of microRNAs (miRNAs) in acquiring resistance to tamoxifen, a drug successfully...
Hormone therapy is one of the most effective breast cancer treatments, however, its application is l...
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality among ...
Cataloged from PDF version of article.Tamoxifen is an endocrine therapy which is administered to up ...
Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of breast tumors...
Breast cancer (BC) is the most common type of malignancy in women. A subset of breast cancers show r...
Resistance to tamoxifen (Tam), a widely used antagonist of the estrogen receptor (ER), is a common o...
Background Endocrine resistance is a major hurdle in breast cancer management, and determining the u...
<div><p>Introduction</p><p>The role of miRNAs in acquired endocrine-resistant breast cancer is not f...
Breast cancer is a hormone-dependent cancer and usually treated with endocrine therapy using aromata...
Abstract Background Tumor resistance to the selective estrogen receptor modulator tamoxifen remains ...
Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast can...
Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast canc...
Abstract no. 151Tamoxifen is a selective estrogen receptor modifier competing for binding with estro...
Poster Session 3 - PO.CB.13.01: MicroRNA-Mediated Regulation of Cancer Biology 2: abstract no. 2040T...
We explored the role of microRNAs (miRNAs) in acquiring resistance to tamoxifen, a drug successfully...
Hormone therapy is one of the most effective breast cancer treatments, however, its application is l...
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality among ...
Cataloged from PDF version of article.Tamoxifen is an endocrine therapy which is administered to up ...
Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of breast tumors...
Breast cancer (BC) is the most common type of malignancy in women. A subset of breast cancers show r...
Resistance to tamoxifen (Tam), a widely used antagonist of the estrogen receptor (ER), is a common o...
Background Endocrine resistance is a major hurdle in breast cancer management, and determining the u...
<div><p>Introduction</p><p>The role of miRNAs in acquired endocrine-resistant breast cancer is not f...